Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells

Full text
Borges, Kleiton Silva [1] ; Castro-Gamero, Angel Mauricio [1] ; Moreno, Daniel Antunes [1] ; Silveira, Vanessa da Silva [2] ; Brassesco, Maria Sol [2] ; de Paula Queiroz, Rosane Gomes [2] ; de Oliveira, Harley Francisco [3] ; Carlotti, Jr., Carlos Gilberto [4] ; Scrideli, Carlos Alberto [2] ; Tone, Luiz Gonzaga [2, 1]
Total Authors: 10
[1] USP, Dept Genet, Sch Med Ribeirao Preto, BR-14048900 Ribeirao Preto, SP - Brazil
[2] USP, Dept Pediat, Sch Med Ribeirao Preto, BR-14048900 Ribeirao Preto, SP - Brazil
[3] USP, Dept Clin Med, Sch Med Ribeirao Preto, BR-14048900 Ribeirao Preto, SP - Brazil
[4] USP, Dept Surg & Anat, Sch Med Ribeirao Preto, BR-14048900 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY; v. 138, n. 3, p. 405-414, MAR 2012.
Web of Science Citations: 31

Glioblastoma remains one of the most devastating human malignancies, and despite therapeutic advances, there are no drugs that significantly improve the patient survival. Altered expression of the Aurora kinases was found in different malignancies, and their inhibition has been studied in cancer therapy. In this study, we analyzed the expression of Aurora A and Aurora B in glioblastoma samples and also analyzed whether the effects of Aurora kinase inhibition were associated with temozolomide or not on cell lines and primary cultures of glioblastoma. RT-PCR assays were used to determine the mRNA expression in glioblastoma tumor samples and in the cell lines. Cell proliferation was measured by XTT assay, and apoptosis was determined by flow cytometry. Drug combination analyses were made based in Chou-Talalay method. Gamma radiation for clonogenic survival used the doses of 2, 4 and 6 Gy. Changes in Aurora B level were assessed by Western blot analysis. Aurora A and B were expressed in glioblastoma samples as well as in the glioblastoma cell lines (n = 6). Moreover, ZM447439, a selective Aurora kinase inhibitor, decreased the proliferation separately and synergistically with temozolomide in primary cultures and cell lines of glioblastoma. ZM also enhanced the effects of radiation on the two cell lines studied (U343 and U251), mainly when associated with TMZ in U343 cells. Treatment with ZM induced apoptotic cell death and diminished Aurora B protein level. These data suggest that Aurora kinase inhibition may be a target for glioblastoma treatment and could be used as adjuvant to chemo- and radiotherapy. (AU)